

HHS Public Access

Author manuscript *Dev Psychobiol.* Author manuscript; available in PMC 2021 May 20.

Published in final edited form as: Dev Psychobiol. 2014 May ; 56(4): 797–811. doi:10.1002/dev.21149.

Salivary Cytokines in Healthy Adolescent Girls: Intercorrelations, Stability, and Associations With Serum Cytokines, Age, and Pubertal Stage

Jenna L. Riis¹, Dorothee Out^{2,3,4}, Lorah D. Dorn⁵, Sarah J. Beal⁶, Lee A. Denson^{7,8}, Stephanie Pabst^{6,7}, Katrin Jaedicke⁹, Douglas A. Granger^{1,2,10}

¹Department of Population, Family and Reproductive Health Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland ²Johns Hopkins School of Nursing, 525 North Wolfe Street Baltimore, Maryland 21205 ³Centre for Child and Family Studies Leiden University, Leiden The Netherlands ⁴Institute for Interdisciplinary Salivary Bioscience Research at Arizona State University ⁵School of Nursing, The Pennsylvania State University, 201 Health and Human Development East University Park, Pennsylvania 16802 ⁶Division of Adolescent Medicine Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio ⁷College of Medicine University of Cincinnati, Cincinnati, Ohio ⁸Division of Pediatric Gastroenterology Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio ⁹Centre for Oral Health Research School of Dental Sciences, Newcastle University, UK ¹⁰Institute for Interdisciplinary Salivary Bioscience Research, Arizona State University, Interdisciplinary Science and Technology Bldg. I, Room 477, 550 E. Orange St. Tempe Arizona 85287

Abstract

Theoretically, the measurement of cytokines in saliva may have utility for studies of brain, behavior, and immunity in youth. Cytokines in saliva and serum were analyzed across three annual assessments in healthy adolescent girls (N = 114, 11–17 years at enrollment). Samples were assayed for GM-CSF, IFN γ , IL-1 β , IL-2, IL-6, IL-8, IL-10, IL-12p70, TNF α , adiponectin, and cotinine. Results revealed: (1) cytokine levels, except IFN γ and IL-10, were detectable in saliva, and salivary levels, except IL-8 and IL-1 β , were lower than serum levels; (2) salivary cytokine levels were lower in older girls and positively associated with adiponectin; (3) compared to serum levels, the correlations between salivary cytokines were higher, but salivary cytokines were less stable across years; and (4) except for IL-1 β , there were no significant serum–saliva associations. Variation in basal salivary cytokine levels in healthy adolescent girls reflect compartmentalized activity of the oral mucosal immune system, rather than systemic cytokine activity.

Correspondence to: Douglas A. Granger, Douglas.Granger@Asu.edu.

Conflict of interest: In the interest of full disclosure, DAG is founder and Chief Strategy and Scientific Advisor at Salimetrics LLC (State College, PA). DAG's relationships with these entities are managed by the policies of the Conflict of Interest Committee at the Johns Hopkins University and the Office of Research Integrity and Assurance at Arizona State University.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.

Keywords

saliva; serum; cytokines; immune markers; adolescent

INTRODUCTION

More so than any other time in recent history, the direction of child and adolescent research is being influenced by theoretical models that emphasize the confluence of biological, behavioral, social, and contextual forces. Our understanding of the mechanisms linking the central and peripheral nervous and immune systems have evolved significantly, leading researchers to consider the nature and implications of effects of these systems on behavior, immunity, and negative health outcomes. However, how these relationships affect child health and development has received scant empirical attention (Granger, Granger, & Granger, 2006; Johnson, Riley, Granger, & Riis, 2013).

Technical advances now enable minimally invasive measurement (in saliva) of many of the intracellular regulatory molecules (i.e., cytokines) responsible for linking communications between the immune system and the central nervous system (CNS), hypothalamic–pituitary–adrenal (HPA) axis, and behavior (see Granger et al., 2012 for review). To date, with a few exceptions (El-Sheikh, Buckhalt, Granger, Erath, & Acebo, 2007; Keller, El-Sheikh, Vaughn, & Granger, 2010) the depth of our knowledge regarding the nature and meaning of individual differences in salivary cytokine levels in youth is extraordinarily shallow. Basic questions related to observed variation, intercorrelations between cytokines, stability over time, and the correlates and concomitants of salivary cytokine measurements in youth remain unanswered. In the present study, we begin to address several knowledge gaps by analyzing cytokines reflecting various components of intercellular and hormonal signaling within the neuro-endocrine-immune (NEI) network in saliva samples.

Conceptual Issues

The history of science linking behavior and psychological states to changes in immune function is well documented (see Ader, 1996, 2000; Irwin, 2008 for reviews). Evidence supporting the veridicality of an immune-CNS link was reported in the 1970–1980s when anatomical pathways were discovered that physiochemically linked the CNS and lymphoid systems. A series of landmark studies (e.g., Granger & Williams, 1968; Hessinger, Daynes, & Granger, 1973) revealed that lymphoid cells secreted soluble chemical messengers (i.e., cytokines) to initiate, maintain, and regulate cellular immune responses. Later it was discovered that these soluble signals (see Maier & Watkins, 1998; Smith, 1992; Vilcek, 1998) also had "hormonal" effects on nonlymphoid cells (e.g., Besedovsky et al., 1983; Besedovsky & del Rey, 1989). For researchers interested in the interactions between the brain, behavior, and immunity, this set of discoveries completed a critically important communication loop. That is, cells of the lymphoid, CNS, and endocrine systems use the same hormones, neurotransmitters, and other critical effector molecules to send and receive signals among one another (see Besedovsky & del Rey, 2007 for review). Decoding the syntax of these communications has enabled theorists to attribute special features to the immune system's functional repertoire. Blalock (e.g., 1994, 1997) has proposed that the immune system recognizes unique environmental stimuli (e.g., viruses, bacteria, microbes, toxins) that are essentially undetectable by our classic sensory systems. Just as is true with our other sensory inputs, when the immune system recognizes such stimuli, the encounter is converted into a cascade of biochemical messages. We now know that those messages are responsible for inducing changes in the host's metabolic, thermogenic, and behavioral states in response to infection. Characterizing the immune system as a "sixth sense" (Blalock & Smith, 2007) highlighted the biological plausibility that communications between the immune system and the brain represent a largely unexplored pathway through which environmental factors (non-self antigens) shape and reshape the structure and function of the biological systems underlying behavior (e.g., Granger et al., 2006).

Primer on Cytokines for Developmental Scientists

Cytokines are protein molecules that act as intercellular messengers which range in size from 8 to 30 kDa and induce their effects by binding to high-affinity receptors on target cell membranes. Monocytes and macrophages are especially efficient cytokine producers. Most cytokine secretion involves de novo protein synthesis, a process that takes hours. Cytokines play important roles in maintaining health and are the causative agents in disease. In addition to regulating immune and inflammatory responses, the biologic consequences of cytokine signaling are critical for development, growth, healing, and maintenance of just about every tissue and organ of the body (Owen, Punt, & Stranford, 2012).

Shared characteristics, such as cytokine structure, common receptor usage, and predominant function (anti-inflammatory, proinflammatory, chemotactic, or growth-promoting) are used to group cytokines into families. Within the immune system, in general, interleukins (e.g., IL-1 β , IL-2, IL-6, IL-8, IL-10, IL-12p70) are molecules that have a functional activity involving leukocytes; colony-stimulating and growth factors (e.g., GM-CSF) promote cell proliferation of hematopoeitic and somatic cells; tumor necrosis factors (e.g., TNFa) initiate inflammation, orchestrate the development and maintenance of lymphoid organs, and regulate lymphocyte homeostasis and proliferation; interferons (e.g., IFN γ) act to interfere with viral replication; and chemokines are chemotactic agents that recruit leukocytes to sites of inflammation and orchestrate lymphoid architecture and leukocyte trafficking (Clough & Roth, 1998; Owen et al., 2012). Cytokines are extremely potent, and their presence even at very low pg/ml levels can induce substantial cellular consequences. A complex set of mechanisms exists to prevent cytokines from doing damage to the host. Inadequate production of cytokines will result in an insufficient cellular immune response and a potentially negative outcome related to pathogenesis of the microbe or virus. On the other hand, excessive cytokine secretion has been linked to "sickness behaviors," autoimmune disorders (e.g., arthritis), neurological disease (e.g., multiple sclerosis), toxic shock, and death (see reviews by Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008; Goldsby, 2003; Thomson & Lotze, 2003).

Cytokines have a variety of effects on cerebral neurotransmission (e.g., Dunn, Wang, & Ando, 1999; Camacho-Arroyo, Lopez-Griego, & Morales-Montor, 2008). IL-1 β stimulates cerebral norepinephrine (NE) metabolism. Together with IL-6 and TNF α , IL-1 β also stimulates indolamine metabolism of tryptophan and decreases the concentration of serotonin. Cytokine-stimulated indolamines also affect the synthesis of quinolinic (QUIN) and kynurenic acid. In the brain, QUIN is an agonist of excitatory amino acid receptors, including the *N*-methyl-D-aspartate (NMDA) receptor. Prolonged activation of these excitatory amino acid receptors in the hippocampus, basal ganglia, and cerebral cortex may damage the nerve cells. In addition to CNS effects of peripheral cytokines, brain cells can release cytokines, and communication between the CNS and immune system is mediated via a direct connection by the vagus nerve (Heyes, 1992; Heyes et al., 1992; Saito, Markey, & Heyes, 1992; Szelényi, 2001).

The effects of cytokines involve changes in neurotransmission in brain regions important for learning and memory, emotion regulation, and the psychobiology of the stress response (i.e., limbic system, hypothalamus) (e.g., Avitsur & Yirmiya, 1999; Dantzer, 2001; Dowlati et al., 2010; Hart, 1988; Moldawer, Andersson, Gelin, & Lundholm, 1988; Opp, Orbal, & Kreuger, 1991; Sparado & Dunn, 1990). In humans, Tyrell and colleagues (Smith et al., 1987; Smith, Tyrell, Coyle, & Higgins, 1988; Smith, Tyrell, Coyle, & Willman, 1987) rigorously documented the adverse effects of experimentally induced respiratory virus infection and cytokine administration on psychomotor performance, mood, and memory.

Cytokines in saliva.—The immune system is organized into anatomically discrete compartments to respond to pathogens present in different body tissues (e.g., blood, mucosal surfaces, intestines, and airways). It is well known that variation in localized immune responses is largely confined to that particular compartment and relatively independent of the more general systemic level of immune activation (e.g., Owen et al., 2012). Therefore, unlike many commonly investigated salivary analytes such as cortisol, the vast majority of variation in cytokines in oral fluid may be produced locally in the oral cavity (Granger et al., 2006; 2012). To the extent this is true, the measurement of salivary cytokine levels may be of questionable value to the study of brain, behavior, and immunity. Consistent with this possibility, and in contrast to the strong serum–saliva associations for many endocrine markers, in studies with adults the serum–saliva correlations for immune markers has been shown to be small to modest (e.g., Nishanian, Aziz, Chung, Detels, & Fahey, 1998). Serum–saliva correlations for cytokines in children and adolescents, however, are unknown.

The Present Study

To our knowledge this is the first study to rigorously and systematically explore the nature, variation, and correlates of salivary cytokines in youth. Saliva samples were collected across three annual assessments in a multi-cohort prospective study of healthy girls aged 11–17 years at the first assessment. Samples were assayed for a representative panel of nine cytokines (GM-CSF, IFN γ , IL-1 β , IL-2, IL-6, IL-8, IL-10, IL-12p70, TNF α) reflecting various components of intercellular and hormonal signaling within the NEI network. It is important to note that, while representative, this panel of cytokines is only a selection of a growing list of intracellular communication molecules (e.g., Commins, Steinke, & Borish,

Page 5

2008; Gadina, Ferguson, & Johnston, 2003). We examine the amount of variation, intercorrelations, and stability over time in these salivary cytokines. Given the expectation that salivary cytokine levels may reflect local-oral mucosal immune activation, we also examined associations between cytokines and a salivary adipokine (adiponectin) related to periodontal health (Iwayama et al., 2012) and controlled for smoking, a health behavior prevalent during adolescence and known to compromise oral health. Further, matching serum cytokine levels were employed to evaluate serum–saliva associations. By controlling for smoking and salivary adiponectin, we test the hypothesis that controlling for oral health improves serum–saliva associations for markers that are at least partly influenced by oral health.

METHODS

Participants

Data were analyzed from a longitudinal study designed to examine the impact of depressive symptoms and substance use on reproductive and bone health across puberty in girls (Dorn et al., 2011; Hillman, Dorn, & Huang, 2010). Using a cross-sequential design (Donaldson & Horn, 1992), a total of 262 girls were enrolled and grouped in four cohorts depending on their age at the first assessment. The first cohort consisted of girls aged 11 years (cohort 11), the girls in the second cohort were 13 years old (cohort 13), the third cohort included girls aged 15 (cohort 15) and the girls in the fourth cohort were 17 years old (cohort 17). Each cohort was assessed annually for three consecutive years (see Table 1). Enrollment took place between December 2004 and October 2007. Girls were recruited from a teen health clinic in a children's hospital in a Midwestern city and its surrounding community. Exclusion criteria for enrollment in the larger study included: (1) pregnancy or breast feeding within 6 months, (2) primary amenorrhea (>16 years), (3) secondary amenorrhea (<6 cycles/year; not due to hormone contraception), (4) body mass index (BMI) <1st percentile or weight >300 pounds, (5) medication/medical disorder influencing bone health (e.g., prednisone, seizure medications), and (6) psychological or cognitive disabilities impairing comprehension or compliance.

Annual assessments of salivary data were analyzed for a subset of girls selected from the larger study who had complete salivary and serum cytokine data (113 girls at year 1, 114 girls at year 2, and 107 girls at year 3). The mean age at the first assessment was 11.35 years (SD = 0.27) for cohort 11, 13.52 (SD = 0.42) for cohort 13, 15.59 (SD = 0.30) for cohort 15, and 17.66 (SD = 0.25) for cohort 17 (see Table 1). The majority of the sample was Caucasian (78% for cohort 11, 64% for cohort 13, 58% for cohort 15, 68% for cohort 17). Socioeconomic status, measured with Hollingshead criteria, averaged 44.33 (SD = 11.78) for cohort 11, 42.68 (SD = 12.80) for cohort 13, 32.21 (SD = 14.33) for cohort 15, and 39.92 (SD = 12.18) for cohort 17. The study was approved by the Institutional Review Board of the children's hospital. Written parental consent was obtained, and each adolescent provided assent.

Procedures

Data were collected in a Clinical Translational Research Center. Lab visits were conducted between 11:30 A.M. and 12:30 P.M. and consisted of a physical examination, anthropometry, blood and saliva sampling, psychosocial questionnaires and interviews, and bone densitometry. Girls were instructed to fast for the 2 hours preceding their visit to the lab. If a participant was menarcheal researchers attempted to reschedule her visit to days 5–9 of her menstrual cycle. Lab visits were also rescheduled if girls reported an infection or acute illness. Saliva samples were collected using Salivettes (Sarsted, NC). For more details regarding the procedures, see Dorn and colleagues (2011).

Measures

Puberty.—Pubertal maturation was determined by physical examination carried out by trained clinicians using visualization and breast palpation and inspection of pubic hair and was categorized by Tanner criteria (Marshall & Tanner, 1969).

Smoking.—Smoking behavior was first determined by questionnaire asking participants to describe their current smoking behavior (i.e., if she had never smoked, tried smoking, used to smoke but stopped, or was currently smoking) (Mayhew, Flay, & Mott, 2000). In addition, tobacco smoke exposure was tested by assaying the saliva samples for cotinine (a primary metabolite of nicotine) using a commercially available enzyme immunoassay without modification to the manufacturer's protocol (Salimetrics, State College, PA). The test used 20 µl of sample, had a lower limit of sensitivity of .05 ng/ml, a range of sensitivity from .05 to 200 ng/ml and an average intra-assay coefficient of variability (CV) of less than 8%. Salivary cotinine was recoded into groups based on reported cutoffs for smoking status (low/ non-smoker = 0–15 ng/ml; smoker >15 ng/ml) (Etzel, 1990; Jarvis, Tunstall-Pedoe, Feyerabend, Vesey, & Salooiee, 1987; Patrick et al., 1994). All adolescents with cotinine levels higher than 15 ng/ml and adolescents who reported that they smoked (irrespective of their cotinine levels) were categorized as "smokers". Adolescents with low cotinine levels (15 ng/ml) and who also reported that they did not smoke were categorized as "nonsmokers." Approximately one quarter of the girls were smokers (year 1: 23% of girls were smokers (26/113); year 2: 22% smokers (25/114); year 3: 27% smokers (29/107)).

Determination of salivary cytokines.—Salivary cytokines were measured using 96well format multiplex electrochemiluminescence immunoassays manufactured by Meso Scale Discovery (MSD, Gaithersburg, MD). Each well of each 96-well plate is coated with capture-antibodies to GM-CSF, IFN γ , TNF α , IL-1 β , IL-2, IL-6, IL-8, IL-10, and IL-12p70. Detection antibodies are coupled to SULFOTAG labels that emit light when electrochemically stimulated via carbon-coated electrodes in the bottom of each microwell. The MSD 9-plex Multi-Spot Array assay was run following the manufacturer's recommended protocol without modification. Cytokine concentrations (pg/ml) were determined with MSD Discovery Workbench Software (v. 3.0.17) using curve fit models (4-PL with a weighting function option of $1/y^2$). Lower limits of detection (LLD) and intraassay CV were as follows: GM-CSF (.26 pg/ml, 14%), IFN γ (3.04 pg/ml, 17%), TNF α (.58 pg/ml, 12%), IL-1 β (.58 pg/ml, 6%), IL-2 (.39 pg/ml, 13%), IL-6 (.21 pg/ml, 12%), IL-8 (.15 pg/ml, 12%), IL-10 (1.01 pg/ml, 8%), and IL-12p70 (.48 pg/ml, 14%).

Determination of salivary adiponectin.—Adiponectin is an endocrine factor secreted by adipose tissue. Studies show adiponectin plays a role in inflammation and immune responses and has a potent beneficial function on the maintenance of the homeostasis of periodontal health (Iwayama et al., 2012; Kraus et al., 2012). We assayed adiponectin using an enzyme immunoassay designed for use with serum (Duoset, R&D Systems, Minneapolis, MN) modified for use with saliva. Samples were assayed at a 1:8 dilution (35 µl volume of saliva was diluted), test volume was 100 µl, standard curve ranged from 62.5 to 2,000 pg/ml, and inter-assay CVs were on average 4.56%. A subset of samples were re-assayed at 1:4 (34/334 samples) or 1:16 (5/334 samples) based on values returned at 1:8 that were below or above the standard curve.

Serum cytokine determinations.—As part of the larger study, the cytokine panel assayed in saliva (described above) had been previously measured in serum using the Luminex platform and Lincoplex methodology without modification to the manufacturer's recommended protocol (Millipore, Billerica, MA). For the serum cytokines, sensitivities were: GM-CSF (.46 pg/ml), TNFa (.05 pg/ml), IL-1 β (.06 pg/ml), IL-2 (.16 pg/ml) IL-6 (.10 pg/ml), IL-8 (.11 pg/ml), IFN γ (.29 pg/ml), IL-10 (.15 pg/ml), and IL-12p70 (.11 pg/ml) with intra-assay CVs ranging from 3% to 6% (see Dorn, Hillman, Houts, Denson, & Pabst, submitted for publication).

Analytic Strategy

A log transformation was applied to all salivary and serum cytokines in order to correct for the positively skewed distribution (see Supplementary Fig. S1 for a graphical representation of salivary cytokine distributions). Any remaining outliers were winsorized (Tabachnik & Fidell, 2001); that is, all values higher than three standard deviations from the mean were replaced with the next highest value in the distribution. The main analyses were conducted using the transformed and winsorized variables. To simplify the presentation, the main analyses report findings from the first assessment year, and results for the second and third assessment years are described only if they differ from those of the first year. The Bonferroni correction was employed for *t* tests and correlations for each set of analyses (within each assessment year) to account for increased Type I error rate in the case of multiple significance tests.

Paired *t* tests were conducted to test whether cytokine levels in saliva were significantly different as compared to serum levels (Bonferroni corrected $\alpha = .007$). Developmental differences in salivary cytokine concentrations were examined within each assessment year by Pearson's correlations to examine the relation with age ($\alpha = .007$) and independent *t* tests to examine the relation with pubertal stage ($\alpha = .007$). Since very few girls were in Tanner Breast Stages 1–4 (34% for assessment year 1, 22% for year 2, and 12% for year 3), we compared levels of salivary cytokines between girls in stages 1–4 and girls in stage 5. The intercorrelations between serum cytokines and between salivary cytokines were examined by calculating partial correlations (controlling for age, $\alpha = .002$) and by principal component analyses (PCA) with promax rotation. Stability in cytokine levels over time and the associations with adiponectin were also evaluated using partial correlations (controlling for age, $\alpha = .007$).

Finally, serum–saliva associations for each of the cytokines were examined by calculating partial correlations (controlling for age, $\alpha = .007$). Then, hierarchical regression analyses were conducted to test whether controlling for age and two indicators of oral health (smoking status and adiponectin) improved the associations between salivary and serum levels of the cytokines within each assessment year. For each salivary cytokine, a regression analysis was performed with age, adiponectin, and smoking status in the first step and the serum levels of the respective cytokine in the second step. Although the transformation and winsorizing improved the distributions of the salivary and serum cytokines substantially, there was still modest positive skewness for some of the variables. Therefore, robust regression analyses were performed, which are designed to be not overly affected by violations of assumptions for least squares regression (e.g., normal distribution, absence of outliers, absence of heterogeneity).

RESULTS

Descriptive Statistics for Salivary and Serum Cytokine Levels

Descriptive statistics (means, standard deviations, minimum and maximum, medians and 25th and 75th percentiles) are presented in Table 2 separately for each salivary cytokine and assessment year, but averaged across age-cohort. Similarly, descriptive statistics for the serum cytokines can be found in Table 3. With the exception of IL-10 and IFN γ , salivary levels were above the lower limit of detection (LLD) in the majority of samples for each cytokine (percentage of values below LLD: 0–49%). Values below the LLD were replaced with zeros, so as to be consistent with previous reports on this sample (Dorn et al., 2011). Salivary IL-10 and IFN γ were excluded from further analyses, because across all assessment years and age-cohorts (a total of 334 samples), 80% and 64% of samples had levels below the LLD for IFN γ and IL-10, respectively.

Within each assessment year, paired *t* tests were conducted to examine whether cytokine levels in saliva were significantly different than serum levels. For the first assessment year, results indicated that salivary levels were significantly lower than those in serum (*p*'s < .007), except for levels of IL-1 β and IL-8 which had salivary levels greater than serum levels (*p*'s < .007). Results were similar for years 2 and 3 with the exception of year 3 concentrations of IL-8 (*p* = .08) and GM-CSF (*p* = .13) which were not significantly different in serum and saliva.

Within each assessment year, Pearson's correlations were calculated to examine developmental differences by age in salivary cytokines. With the exception of IL-12p70 at year 1, IL-1 β at years 1 and 2, and IL-2 and IL-6 at year 2, older girls had lower levels of all salivary cytokines at years 1 and 2 (for year 1: r[111] = -.40 to -.24, p's < .007; for year 2: r[112] = -.34 to -.20, p's < .007). At year 3, however, there were no significant correlations between age and salivary cytokine levels.

Independent *t* tests examining differences in salivary cytokine levels between early (Tanner Breast Stages 1–4 (year 1, n = 38; year 2, n = 25; year 3, n = 13)) and late (Tanner Breast Stage 5 (year 1, n = 75; year 2, n = 88; year 3, n = 93)) pubertal development showed similar findings. Lower cytokine concentrations in saliva were associated with more mature pubertal

stage for most cytokines in assessment year 1 (p's < .007 for all cytokines except IL-12p70 which showed no association with pubertal stage (p = .09)). For year 2, IL-12p70, IL-2, IL-8, TNFa, and GM-CSF showed this same pubertal maturity association, however only IL-8 and GM-CSF remained statistically significant after applying the Bonferroni correction (p's < .007). The remaining cytokines, IL-6 and IL-1 β , showed no association with pubertal stage in year 2 (p = .32 and p = .12, respectively). In contrast, in year 3, only IL-8 (p = .02) and GM-CSF (p = .008) were negatively related to pubertal stage, but these associations did not remain statistically significant after adjusting for multiple significance tests.

Intercorrelations of Cytokines

Salivary cytokines were strongly and positively intercorrelated (Table 4) for the first assessment year, with partial correlations (controlling for age) ranging between .51 (df = 110, p < .002) and .93 (df = 110, p < .002). A PCA for salivary cytokines in year 1 pointed to one underlying component, explaining 75% of the variance in cytokine levels. Standardized component loadings ranged between .77 and .95. Results were similar for the second and third year: partial correlations ranged between .42 (df = 111, p < .002) and .92 (df = 111, p < .002) for the second year and between .39 (df = 104, p < .002) and .87 (df = 104, p < .002) for the third assessment year. Similarly, the PCAs for the second and third years also pointed to one underlying component explaining 72% and 65% of the variance in salivary cytokines, respectively.

By contrast, for serum cytokines, most of the partial correlations were modest (see Table 4) at the first assessment year, ranging between .20 (df = 110, p = .04) and .89 (df = 110, p< .002). A PCA with promax rotation for serum cytokines in year 1 pointed to two underlying components which explained in total 73% of the variance. The first component included the cytokines IL-12p70, IL-1β, IL-2, IL-6, and GM-CSF (standardized component loadings between .74 and .87), whereas the second component consisted of IL-8 and TNFa (standardized component loadings: .63 and .75, respectively). For the second and third assessment years, partial correlations were comparable, ranging between .10 (IL-12p70 and TNF α , df = 111, p = .31) and .82 (IL-1 β and IL-2, df = 111, p < .002) for the second year and between -.11 (IL-8 and GM-CSF, df = 104, p = .25) and .65 (IL-2 and IL-6, df = 104, p< .002) for the third year. A PCA with promax rotation for year 2 concentrations revealed a similar component structure to year 1 cytokines; 69% of the variance was explained by two underlying components each made up of the same cytokines groupings as year 1 cytokines. A PCA with promax rotation for year 3 cytokines also pointed to two components explaining 73% of the variance. However, unlike assessment years 1 and 2, in year 3 IL-12p70, IL-2, IL-6, IL-8, and TNFa loaded on the first component (standardized component loadings between .64 and .89), and IL-1ß and GM-CSF loaded on the second component (standardized component loadings: .75 and .78, respectively).

Stability of Individual Differences in Cytokines Across Assessment Years

As can be seen in Table 5, salivary cytokines were modestly associated over time. On average, the size of the partial correlation (controlling for age) for the stability across a 1-year period was .30 (assessment years 1 and 2; r[110] = .21 to .38, p = .03 to <.007) and .25

(years 2 and 3; r[104] = .09 to .36, p = .34 to <.007). The coefficients for the stability across a two-year period averaged .34 (r[103] = .19 to .46, p's = .06 to <.007).

By contrast, for serum cytokines the size of the coefficients between assessment years 1 and 2, years 2 and 3, and years 1 and 3 were, on average .61 (r[110] = .39 to .75, p's < .007), .33 (r[104] = .10 to .54, p = .39 to <.007) and .40 (r[103] = .16 to .57, p = .05 to <.007), respectively. Noteworthy is the observation that individual differences in levels of IL-12p70, IL-1 β , IL-2, and IL-6 were more stable over time when measured in serum than in saliva.

Cytokines and Salivary Adiponectin

Table 6 presents correlation coefficients for the association between salivary adiponectin and each salivary and serum cytokine, controlling for age, at the first assessment year. For every salivary cytokine, there was a significant and strong positive association between cytokine level and adiponectin (r[110] = .46 to .77, p's < .007). In striking contrast, there was no significant association between salivary adiponectin and any cytokine measured in serum (r [110] = -.08 to .00, p's = .38 to >.99). Results were similar for the second and third assessment years.

Serum–Saliva Associations

No significant saliva-serum correlations were found for any cytokine in assessment year 1 (r [110] = -.11 to .11, p's = .24 to .92; Table 7), and similar results were found for years 2 and 3. Hierarchical regressions revealed that the predictors from the first step (age, adiponectin, and smoking status) significantly predicted levels of salivary IL-12p70 (F[3, 109] = 19.30, p < .01), IL-1 β b (F[3, 109] = 61.12, p < .01), IL-2 (F[3, 109] = 51.78, p < .01), IL-6 (F[3, 109] = 19.56, p < .01), IL-8 (F[3, 109] = 74.03, p < .01), TNFa (F[3, 109] = 25.27, p < .01), and GM-CSF (F[3, 109] = 50.83, p < .01) in the first assessment year (Table 8). For all salivary cytokines, adiponectin was significantly associated with cytokine levels (t = 5.80 to 14.73, p's < .01). Older girls had significantly lower levels of IL-8, TNFa, and GM-CSF (t = -3.43 to -2.35, p's < .03), and this association was marginally significant for IL-2 (t = -1.96, p = .05). Also, current smokers had lower levels of GM-CSF (t = -2.46, p = .02) and marginally lower levels of IL-6 (t = -1.87, p = .06). In contrast, for all cytokines serum levels of the respective cytokine did not significantly predict salivary levels after controlling for age, adiponectin, and smoking status in the first assessment year (t = -.87 to 1.61, p's > .05).

Results were similar for the second and third assessment years. However, differences between years were seen in the relation between smoking status and salivary cytokine concentrations. IL-1 β was higher in smokers than non-smokers in year 2 (t = 2.67, p < .01), and IL-1 β , IL-2, and IL-6 were higher in smokers than non-smokers in year 3 (t = 2.24 to 3.17, p < .03). However, unlike in year 1, in years 2 and 3 there were no associations between GM-CSF levels and smoking status (p > .05). Also, in addition to the age effects seen at year 1, at year 2 IL-12p70 was negatively associated with age (t = -3.07, p < .01), and at year 3 the negative relation between IL-2 and age reached significance (t = -2.22, p = .03). Also, in year 3 serum concentrations of IL-1 β were significantly positively associated

with salivary concentrations of IL-1 β (t = 2.30, p = .02) after adjusting for age, smoking status, and salivary adiponectin levels.

DISCUSSION

To the best of our knowledge, this is the first study to rigorously examine serum-saliva cytokines among healthy adolescents. The findings provide important information about salivary cytokines' measurement and concentrations, intercorrelations, stability, and associations with individual factors and other analytes, including serum-saliva correlations. Measurement and concentrations: The results reveal that levels of cytokines, except IFN γ and IL-10, were detectable in the majority of saliva samples, but that the distributions of salivary cytokines were non-normal in every case. The levels of all cytokines were lower in saliva than serum, except IL-8 and IL-1β. Salivary levels for these two cytokines were more than 20-times higher than other salivary cytokines. Intercorrelations: The intercorrelations between cytokines in saliva were higher than in serum, and the factor structure in saliva was also distinct from that in serum with a single component explaining individual differences in the salivary cytokines. Stability across time: Cytokine levels were more stable across years when measured in serum than in saliva. Cytokine associations with individual factors and other analytes: Using adiponectin as a marker of oral health, there were strong associations between salivary adjoent and salivary, but not serum, cytokines. Some of the salivary cytokines were inversely associated with age and pubertal stage. Cytokine serum-saliva associations: Surprisingly, only IL-1ß showed a significant serum-saliva correlation, and, although statistically significant, the magnitude of the association was negligible. Also, this finding was not consistent across assessment years and was only revealed in hierarchical regressions after controlling for age, adiponectin, and smoking status. Overall the findings suggest that variation in basal salivary cytokine levels in healthy adolescents largely reflects compartmentalized local inflammatory activity of the oral mucosal immune system.

At the practical measurement level, for the majority of saliva samples, the cytokine values fell within the dynamic range of measurement afforded by the MSD multi-plex electrochemoluminescence immunoassay platform. For salivary IFN γ and IL-10, however, levels were below the detection limit (<1.0 pg/ml) for the majority of the samples and consistently so across the assessment years. This observation highlights the possibility that it may not be worthwhile to include measures of IFN γ and IL-10 in future studies of salivary cytokines in healthy adolescent girls. Also, the distributions of all cytokines in saliva were non-normal. Therefore, the salivary cytokine data required intensive restructuring and transformation so as not to violate assumptions of normality in statistical analyses. The description of these atypical distributions has important implications for estimating statistical power when planning studies, how salivary cytokine data are prepared prior to data analyses (i.e., transformation and dealing with statistical outliers), as well as for the selection of appropriate parametric or non-parametric statistical techniques.

Serum levels of cytokines were higher than levels in saliva for all cytokines except IL-1 β and IL-8. Levels of IL-1 β and IL-8 were more than 20–25 times the levels of the other salivary cytokines. The literature on oral immunology suggests that IL-8 is a chemotactic factor that influences the migration of neutrophils and increases their concentration (Bickel,

1993). Also, IL-1 β is important for the activation of neutrophils (Shaftel et al., 2007; Struyf et al., 1998). Neutrophils are the most prevalent type of phagocyte in circulation and in whole saliva (Raeste, 1972). Their granules contain proteins, proteolytic enzymes, defensins, and myeloperoxidases that kill bacteria, break down bacterial proteins and cell walls, and stimulate phagocytosis of IgG-coated bacteria (see Owen et al., 2012). The oral compartment is home to hundreds of species of bacteria, and the migration and activation of neutrophils plays a major role in promoting and maintaining oral health. The high levels of IL-8 and IL-1 β observed in the current study likely reflect this important role of neutrophils in oral health.

On average, the correlations between the various cytokines in saliva were higher than the intercorrelations among the same cytokines when measured in serum. The PCA findings confirm two principal components that explain the majority (65–75%) of the variance in cytokines when measured in serum. By contrast, there was just a single component to the structure of the variation in cytokines when they are measured in saliva. Moreover, the intracorrelations for each cytokine over time were stronger for cytokines measured in serum than in saliva, and there was only negligible evidence of any serum-saliva correlation. Oral biologists consider the mouth the most complex microbial microenvironment in the body (Giannobile et al., 2009; Zhang, Henson, Camargo, & Wong, 2009). The oral mucosa immune system is exposed to a wide variety of non-self antigens including bacteria, fungi, viruses, and toxins. Thus, in contrast to circulating blood, oral fluid is not sterile. It is tempting to speculate that because of compartmentalized host-microbe interactions, salivary cytokines reflect a variable environmental microbial influence in the oral compartment, compared to more stable genetic influences on serum cytokines in these healthy adolescents in the sterile serum compartment. Collectively the findings of the study suggest that compartmentalized cytokine activity in the mouth of healthy individuals may be more pronounced and variable than in the systemic immune system.

All salivary cytokines were strongly associated with salivary adiponectin. Although the current study did not assess periodontal disease at the time of saliva collection, studies suggest that adiponectin may play a role in maintaining periodontal health (Iwayama et al., 2012). The fact that all salivary, but not serum, cytokine levels were correlated with adiponectin and that these correlations were very strong is particularly noteworthy. We interpret these findings as confirmatory evidence that salivary cytokine levels largely reflect the degree of local oral, rather than systemic, inflammation; a point crucial for developmental scientists. Future studies should asses the level of periodontal disease and the overall oral health of participants to further our understanding of salivary cytokines and their relevance in developmental science research.

There were no associations between serum and saliva levels of cytokines. It is especially important to note that this was largely true even after controlling for age, adiponectin and smoking status. However, the fact that only IL-1 β showed an association between levels in serum and saliva should not go unnoticed. As noted above, serum levels of IL-1 β play a major role in communication within and across the NEI (Smith, 1992; Weiss, Quan, & Sundar, 1994). It could be that in the case of systemic inflammation (e.g., sepsis, fever, infection), the serum–saliva association for IL-1 β would have been stronger and more

consistent across assessment years. Interestingly, studies show that IL-1β released by cells in the gingival crevicular gap (the space between the gum line and the tooth) during the course of periodontal disease moves into circulation and stimulates the liver to secrete C-reactive protein (CRP) (Megson, Fitzsimmons, Dhamapatri, & Bartold, 2010). At least one study suggests modest serum–saliva correlations for CRP (Out, Hall, Granger, Page, & Woods, 2012; see also Floriano et al., 2009; Punyadeera, Dimeski, Kostner, Beyerlein, & Cooper-White, 2011; Quellet-Morin, Danese, Williams, & Arseneault, 2011). The next generation of studies might explore these serum–saliva relationships in special circumstances and cases representing confirmed systemic or oral inflammatory disease, or both. For instance, in early childhood when the rate of oral health problems is so low, do levels of salivary cytokines more accurately reflect levels in the circulation? What about disease states where the levels of cytokines in blood are atypically high, is the serum–saliva association during these special physiological circumstances stronger? How do salivary cytokines respond to challenge: can similar stress-reactivity patterns be observed in salivary cytokines as for serum cytokines?

Interestingly, both age and pubertal stage were largely associated with salivary cytokine levels. Older and more pubertally mature girls had lower levels of most salivary cytokines, particularly in assessment years 1 and 2. These findings raise the possibility that inflammation in the oral mucosa is associated with hormonal changes associated with girls' pubertal transition. For instance, studies show the rate of inflammatory autoimmune diseases to be higher in females than males, and implicate differences in estradiol levels as a mechanism partially responsible for this robust gender difference (Fairweather, Frisancho-Kiss, & Rose, 2008). Unfortunately, pubertal relations with salivary cytokine levels could not be fully explored in this sample, because the range in pubertal stage was very restricted, particularly at assessment year 3 (i.e., most girls were in advanced pubertal stages). The lack of age and puberty effects at assessment year 3 may be due to smoking in our sample. Older and more pubertally mature girls were more likely to smoke, and therefore, they are more likely to have compromised oral health (Azar & Richard, 2011; Heikkinen et al., 2008, 2012; Lee, Taneja, & Vassallo, 2012). Poorer oral health may be especially pronounced at the third assessment year when the sample is the oldest. Although the sample size within each age group was too small to adequately test the effect of smoking on salivary cytokine levels, it is possible that the effects of age and puberty at year 3 were masked by smokingrelated changes in salivary cytokine concentrations. Larger studies that follow girls (and boys) through this developmental phase and monitor reproductive hormones and salivary cytokines might prove important for understanding developmental changes in salivary cytokines and risk for periodontal disease in adolescence. Future studies should also collect information regarding smoking behavior and duration from adolescent smokers to investigate the impact of smoking on salivary cytokines during this period of developmental change.

Finally, there are several methodological issues related to the assessment of cytokines in saliva that need to be addressed in future studies. In the current study, samples were collected using Salivettes (Sarstedt, NC). However, to our knowledge, no study has examined whether levels of salivary cytokines differ between types of collection devices (e.g., cotton or synthetic swabs) and between passive drool and absorbent materials. Williamson, Munro, Pickler, Grap, and Elswick (2012) examined the levels of 27 cytokines

collected by passive drool and on filter paper. Correlations varied substantially, with moderate to high correlations for IL-1 β , IL-8, and IL-10, and low and non-significant correlations for TNF- α , GM-CSF, and IL-2. Clearly, these results call for more research, focusing on the effects of different saliva collection protocols as well as other methodological issues (e.g., effect of flow rate and mechanical stimulation).

In conclusion, cytokines in saliva show different levels, stability, inter-relationships, and associations with oral health than serum cytokines. There is little evidence of a serum–saliva association under conditions of general health. Collectively, the pattern of findings suggests that basal levels of salivary cytokines reflect activity of a highly compartmentalized oral mucosal immune system. In these circumstances, the value of salivary cytokines to the study of brain, behavior, and immunity may be questionable. Future studies may examine whether this is also true in other physiological states, developmental stages, and stressed versus resting conditions. The observed variation in salivary cytokines in these circumstances may be more likely to reflect systemic processes and be reliably associated with child development, behavior and health. In the current study, focusing on a healthy and non-stressed sample of adolescent girls, our findings highlight the importance of measuring salivary cytokines to advance our understanding of risk for oral health and disease during adolescence and raise important questions about the role of salivary cytokines in intracellular and hormonal signaling within the larger NEI network.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

D.O. was supported by a Rubicon award (446-10-026) from the Netherlands Organization for Scientific Research. This work was supported in part by funding from the National Institutes of Health (R01 DA16402, R21 DA025312; PI: Dorn) and by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8 UL1 TR000077-04. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors wish to thank Tracey Hand and Jessica Bayer at the JHU Center for Interdisciplinary Salivary Bioscience Research for their advanced technical support with the salivary multiplex immunoassays.

REFERENCES

- Ader R (1996). Historical perspectives on psychoneuroimmunology. In Friedman H, Klein TW, & Friedman AL (Eds.), Psychoneuroimmunology, stress, and infection (pp. 1–24). New York: CRC Press.
- Ader R (2000). On the development of psychoneuroimmunology. European Journal of Pharmacology, 405(1–3), 167–176. doi: 10.1016/S0014-2999(00)00550-1 [PubMed: 11033324]
- Avitsur R, & Yirmiya R (1999). The immunobiology of sexual behavior: Gender differences in the suppression of sexual activity during illness. Pharmacology Biochemistry and Behavior, 64(4), 787– 796. doi: 10.1016/S0091-3057(99)00165-3
- Azar R, & Richard A (2011). Elevated salivary C-reactive protein levels are associated with active and passive smoking in healthy youth: A pilot study. Journal of Inflammation, 8(37), 1–8. doi: 10.1186/1476-9255-8-37 [PubMed: 21272292]
- Besedovsky H, del Rey A, Sorkin E, Da Prada M, Burri R, & Honegger C (1983). The immune response evokes changes in brain noradrenergic neurons. Science, 221 (4610), 564–566. doi: 10.1126/science.6867729 [PubMed: 6867729]

- Besedovsky HO, & del Rey A (1989). Mechanism of virus-induced stimulation of the hypothalamus– pituitary–adrenal axis. Journal of Steroid Biochemistry, 34(1–6), 235–239. doi: 10.1016/0022-4731(89)90087-3 [PubMed: 2560513]
- Besedovsky HO, & del Rey AD (2007). Physiology of psychoneuroimmunology: A personal view. Brain, Behavior, and Immunity, 21(1), 34–44. doi: 10.1016/j.bbi.2006.09.008
- Bickel M (1993). The role of IL-8 in inflammation and mechanisms of regulation. Journal of Periodontology, 64(5 Suppl), 456–460. Retrieved from http://www.joponline.org/loi/jop [PubMed: 8315568]
- Blalock JE (1997). The syntax of immune-neuroendocrine communication. Immunology Today, 15(11), 504–511. doi: 10.1016/0167-5699(94)90205-4
- Blalock JE (1994). The immune system: Our sixth sense. The Immunologist, 2, 8–15.
- Blalock JE, & Smith EM (2007). Conceptual development of the immune system as a sixth sense. Brain, Behavior, and Immunity, 21(1), 23–33. doi: 10.1016/j.bbi.2006.09.004
- Camacho-Arroyo I, Lopez-Griego L, & Morales-Montor J (2008). The role of cytokines in the regulation of neurotransmission. Neuroimmunomodulation, 16(1), 1–12. doi: 10.1159/000179661 [PubMed: 19077440]
- Commins S, Steinke JW, & Borish L (2008). The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. Journal of Allergy and Clinical Immunology, 121(5), 1108–1111. doi: 10.1016/j.jaci.2008.02.026
- Clough NC, & Roth JA (1998). Understanding Immunology. St. Louis, MN: Mosby-Year Book, Inc.
- Dantzer R (2001). Cytokine-induced sickness behavior: Where do we stand? Brain, Behavior, and Immunity, 15(1), 7–24. doi: 10.1006/brbi.2000.0613
- Dantzer R, O'Connor JC, Freund GG, Johnson RW, & Kelley KW (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56. doi: 10.1038/nrn2297 [PubMed: 18073775]
- Donaldson G, & Horn JL (1992). Age, cohort, and time developmental muddles: Easy in practice, hard in theory. Experimental Aging Research, 18(4), 213–222. doi: 10.1080/03610739208260360 [PubMed: 1459165]
- Dorn LD, Hillman J, Houts R, Denson L, & Pabst S Variability in cytokines in healthy adolescent girls: Newly applied analytic strategies to capture characteristics of the individual person and immune function. Journal of Pediatrics (submitted for publication).
- Dorn LD, Pabst S, Sontag LM, Kalkwarf HJ, Hillman JB, & Susman EJ (2011). Bone mass, depressive, and anxiety symptoms in adolescent girls: Variation by smoking and alcohol use. Journal of Adolescent Health, 49(5), 498–504. doi: 10.1016/j.jadohealth.2011.03.008
- Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, & Lanctôt KL (2010). A metaanalysis of cytokines in major depression. Biological Psychiatry, 67(5), 446–457. doi: 10.1016/ j.biopsych.2009.09.033 [PubMed: 20015486]
- Dunn AJ, Wang J, & Ando T (1999). Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Advances in Experimental Medicine and Biology, 461, 117–127. Retrieved from http://link.springer.com/bookseries/5584 [PubMed: 10442171]
- El-Sheikh M, Buckhalt JA, Granger DA, Erath SA, & Acebo C (2007). The association between children's sleep disruption and salivary interleukin-6. Journal of Sleep Research, 16(2), 188–197. doi: 10.1111/j.1365-2869.2007.00593.x [PubMed: 17542949]
- Etzel J (1990). A review of the use of saliva cotinine as a marker of tobacco smoke exposure. Prevention Medicine, 19(2), 190–197. doi: 10.1016/0091-7435(90)90020-K
- Fairweather D, Frisancho-Kiss S, & Rose NR (2008). Sex differences in autoimmune disease from a pathological perspective. American Journal of Pathology, 173(3), 600–609. doi: 10.2353/ ajpath.2008.071008
- Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, ... McDevitt JT (2009). Use of saliva-based nanobiochip tests for acute myocardial infarction at the point of care. A feasibility study Clinical Chemistry, 55(8), 1530–1538. doi: 10.1373/clinchem.2008.117713 [PubMed: 19556448]

- Gadina M, Ferguson PR, & Johnston JA (2003). New interleukins: Are there any more? Current Opinion in Infectious Diseases, 16(3), 211–217. doi: 10.1097/01.qco.0000073769.11390.ea [PubMed: 12821810]
- Giannobile WV, Beikler T, Kinney JS, Ramseier CA, Morelli T, & Wong DT (2009). Saliva as a diagnostic tool for periodontal disease: Current state and future directions. Periodontology 2000, 50(1), 52–64. doi: 10.1111/j.1600-0757.2008.00288.x [PubMed: 19388953]

Goldsby RA (2003). Immunology (5th ed.). New York: Freeman.

- Granger DA, Fortunato CK, Beltzer EK, Virag M, Bright MA, & Out D (2012). Focus on methodology: Salivary bioscience and research on adolescence: An integrated perspective. Journal of Adolescence, 35(4), 1081–1095. doi: 10.1016/j.adolescence.2012.01.005 [PubMed: 22401843]
- Granger DA, Granger GA, & Granger SW (2006). Immunology and developmental psychopathology. In Cicchetti D & Cohen D (Eds.), Developmental psychopathology, Vol. 2. Developmental neuroscience (pp. 677–709). New York: John Wiley & Sons.
- Granger DA, Kivlighan KT, Blair C, El-Sheikh M, Mize J, Lisonbee JA, & Schwartz EB (2006). Integrating the measurement of salivary-amylase into studies of child health, development, and social relationships. Journal of Personal and Social Relationships. Special Issue: Physiology and Human Relationships, 23(2), 267–290. doi: 10.1177/0265407506062479
- Granger GA, & Williams TW (1968). Lymphocyte cytotoxicity in vitro: Activation and release of a cytotoxic factor. Nature, 218(5148), 1253–1254. Retrieved from http://www.nature.com/nature/ index.html [PubMed: 5656652]
- Hart BL (1988). Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Review, 12(2), 123–137. doi: 10.1016/S0149-7634(88)80004-6
- Heikkinen AM, Pajukanta R, Pitkaniemi J, Broms U, Sorsa T, Koskenvuo M, & Meurman JH (2008). The effect of smoking on periodontal health of 15- to 16-year-old adolescents. Journal of Periodontology, 79(11), 2042–2047. doi: 10.1902/jop.2008.080205 [PubMed: 18980511]
- Heikkinen AM, Pitkaniemi J, Kari K, Pajukanta R, Elonheimo O, Koskenvuo M, & Meurman JH (2012). Effect of teenage smoking on the prevalence of periodontal bacteria. Clinical Oral Investigation, 16(2), 571–580. doi: 10.1007/s00784-011-0521-3
- Hessinger DA, Daynes RA, & Granger GA (1973). Binding of human lymphotoxin to target-cell membranes and its relation to cell-mediated cytodestruction. Proceedings of the National Academy of Sciences United States of America, 70(11), 3082–3086. Retrieved from http://www.pnas.org/
- Heyes MP (1992). Quinolinic acid in culture media used for in vitro neurotoxicology studies. Neuroscience Letters, 145(2), 234–235. doi: 10.1016/0304-3940(92)90030-B [PubMed: 1465223]
- Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, ... Tourtellotte WW, (1992). Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain, 115(5), 1249–1273. doi: 10.1093/brain/115.5.1249 [PubMed: 1422788]
- Hillman JB, Dorn LD, & Huang B (2010). Association of anxiety and depressive symptoms and adiposity among adolescent females, using dual energy X-ray absorptiometry. Clinical Pediatrics, 49(7), 671–677. doi: 10.1177/0009922810363155 [PubMed: 20356924]
- Irwin MR (2008). Human psychoneuroimmunology: 20 years of discovery. Brain, Behavior, and Immunity, 22(2), 129–139. doi: 10.1016/j.bbi.2007.07.013
- Iwayama T, Yanagita M, Mori K, Sawada K, Ozasa M, Kubota M, ... Murakami S (2012). Adiponectin regulates functions of gingival fibroblasts and periodontal ligament cells. Journal of Periodontal Research, 47(5), 563–571. doi: 10.1111/j.1600765.2012.01467.x [PubMed: 22339084]
- Jarvis M, Tunstall-Pedoe H, Feyerabend C, Vesey C, & Saloojee Y (1987). Comparison of tests used to distinguish smokers from nonsmokers. American Journal of Public Health, 77(11), 1435–1438. Retrieved from http://ajph.aphapublications.org/loi/ajph/ [PubMed: 3661797]
- Johnson SB, Riley AW, Granger DA, & Riis JL (2013). The science of early life toxic stress for pediatric practice. Pediatrics, 131, 319–327. doi: 10.1542/peds.2012-0469 [PubMed: 23339224]
- Keller PS, El-Sheikh M, Vaughn B, & Granger DA (2010). Relations between mucosal immunity and children's mental health: The role of child sex. Physiology & Behavior, 101(5), 705–712. doi: 10.1016/j.physbeh.2010.08.012 [PubMed: 20732336]

- Kraus D, Winter J, Jepsen S, Jager A, Meyer R, & Dreschner J (2012). Interactions of adiponectin and lipopolysaccharide from porphyromonas gingivalis on human oral epithelial cells. PLoS ONE, 7(2), e30716. doi: 10.1371/journal.pone.0030716 [PubMed: 22319581]
- Lee J, Taneja V, & Vassallo R (2012). Cigarette smoking and inflammation: Cellular and molecular mechanism. Critical Reviews in Oral Biology and Medicine, 91(12), 142–149. doi: 10.1177/0022034511421200
- Maier SF, & Watkins LR (1998). Cytokines for psychologists: Implications of bidirectional immuneto-brain communication for understanding behavior, mood, and cognition. Psychological Review, 105(1), 83–107. doi: 10.1037/0033-295X.105.1.83 [PubMed: 9450372]
- Marshall WA, & Tanner JM (1969). Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood, 44(235), 291–303. Retrieved from http://adc.bmj.com/ [PubMed: 5785179]
- Mayhew KP, Flay BR, & Mott JA (2000). Stages in the development of adolescent smoking. Drug and Alcohol Dependence, 59(Suppl. 1), S61–S81. doi: 10.1016/S0376-8716(99)00165-9 [PubMed: 10773438]
- Megson E, Fitzsimmons T, Dharmapatni K, & Bartold PM (2010). C-reactive protein in gingival crevicular fluid may be indicative of systemic inflammation. Journal of Clinical Periodontology, 37(9), 797–804. doi: 10.1111/j.1600-051X.2010.01603.x [PubMed: 20618548]
- Moldawer LL, Andersson C, Gelin J, & Lundholm KG (1988). Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. American Journal of Physiology, 254(3), G450–G456. Retrieved from http://ajpgi.physiology.org/
- Nishanian P, Aziz N, Chung J, Detels R, & Fahey JL (1998). Oral fluids as an alternative to serum for measurement of immune activation. Clinical and Diagnostic Laboratory Immunology, 5(4), 507– 512. Retrieved from http://cvi.asm.org/ [PubMed: 9665958]
- Opp MR, Orbal F, & Kreuger JM (1991). Interleukin-1 alters rat sleep: Temporal and dose-related effects. American Journal of Physiology, 260(1), R52–R58. Retrieved from http://ajpregu.physiology.org/
- Out D, Hall RJ, Granger DA, Page GG, & Woods SJ (2012). Assessing salivary C-reactive protein: Longitudinal associations with systemic inflammation and cardiovascular disease risk in women exposed to intimate partner violence. Brain, Behavior and Immunity, 26(4), 543–551. doi: 10.1016/j.bbi.2012.01.019
- Owen J, Punt J, & Stranford S (2012). Kuby immunology (7th ed.). New York, NY: W. H. Freeman.
- Patrick DL, Cheadle A, Thompson DC, Dieher P, Koepsell T, & Kinne S (1994). The validity of self-reported smoking: A review and meta-analysis. American Journal of Public Health, 84(7), 1086–1093. Retrieved from http://ajph.aphapublications.org/loi/ajph [PubMed: 8017530]
- Punyadeera C, Dimeski G, Kostner K, Beyerlein P, & Cooper-White J (2011). One-step homogeneous C-reactive protein assay for saliva. Journal of Immunological Methods, 373(1), 19–25. doi: 10.1016/j.jim.2011.07.013 [PubMed: 21821037]
- Quellet-Morin I, Danese A, Williams B, & Arseneault L (2011). Validation of a high-sensitivity assay for C-reactive protein in human saliva. Brain, Behavior, and Immunity, 25(4), 640–646. doi: 10.1016/j.bbi.2010.12.020
- Raeste AM (1972). The differential count of oral leukocytes. European Journal of Oral Sciences, 80(1), 63–67. doi: 10.1111/j.1600-0722.1972.tb00263.x
- Saito K, Markey SP, & Heyes MP (1992). Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience, 15(1), 25–39. doi: 10.1016/0306-4522(92)90467-G
- Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, & O'Banion MK (2007). Chronic interleukin-1 expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood–brain barrier permeability without overt neurodegeneration. The Journal of Neuroscience, 27(35), 9301–9309. doi: 10.1523/JNEUROSCI.1418-07.2007 [PubMed: 17728444]
- Smith A, Tyrell D, Coyle K, & Higgins P (1988). Effects of Interferon alpha on performance in man: A preliminary report. Psychopharmacology, 96(3), 414–416. Retrieved from http://link.springer.com/ journal/213 [PubMed: 3146777]
- Smith AP, Tyrell DA, Al-Nakib W, Coyle KB, Donovan CB, Higgins PG, & Willman JS (1987). Effects of experimentally induced respiratory virus infection and illness on psychomotor

performance. Neuropsychobiology, 18(3), 144–148. Retrieved from http://content.karger.com/ ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=224082 [PubMed: 3453430]

- Smith E (1992). Hormonal effects of cytokines. In: Blalock JE (Ed.), Neuroimmunoendocrinology (pp. 154–169). New York: Krager.
- Smith RW, Tyrell D, Coyle K, & Willman JS (1987). Selective effects of minor illnesses on human performance. British Journal of Psychology, 78(Pt 2), 183–188. Retrieved from http:// onlinelibrary.wiley.com/journal/10.1111/(ISSN)2044-8295 [PubMed: 3594089]
- Sparado F, & Dunn AJ (1990). Intracerebroventricular administration of interleukin-1 to mice alters investigation of stimuli in a novel environment. Brain, Behavior, and Immunity, 4(4), 308–322. doi: 10.1016/0889-1591(90)90034-N
- Struyf S, Coillie EV, Paemen L, Put W, Lenaerts J-P, Proost P, ... Van Damme J, (1998). Synergistic induction of MCP-1 and -2 by IL-1b and interferons in fibroblasts and epithelial cells. Journal of Leukocyte Biology, 63(3), 364–372. Retrieved from: http://www.jleukbio.org/ [PubMed: 9500525]
- Szelényi J (2001). Cytokines and the central nervous system. Brain Research Bulletin, 54(4), 329–338. doi: 10.1016/S0361-9230(01)00428-2 [PubMed: 11306183]
- Tabachnik BG, & Fidell LS (2001). Using multivariate analysis (4th ed.). Boston, MA: Allyn and Bacon.
- Thomson A, & Lotze MT (2003). The cytokine handbook(4th ed.). San Diego, CA: Academic Press.
- Vilcek J (1998). The cytokines: An overview. In Thomson AW (Ed.), The cytokine handbook (pp. 1–20). San Diego: Academic Press.
- Williamson S, Munro C, Pickler R, Grap MJ, & Elswick RK Jr., (2012). Comparison of biomarkers in blood and saliva in healthy adults. Nursing Research and Practice, 2012, 1–4. doi: 10.1155/2012/246178
- Weiss JM, Quan N, & Sundar SK (1994). Widespread activation and consequences of interleukin-1 in the brain. Annals of the New York Academy of Sciences, 741, 338–357. doi: 10.1111/ j.1749-6632.1994.tb39676.x [PubMed: 7825822]
- Zhang L, Henson BS, Camargo PM, & Wong DT (2009). The clinical value of salivary biomarkers for periodontal disease. Periodontology 2000, 51(1), 25–37. doi: 10.1111/j.1600-0757.2009.00315.x [PubMed: 19878467]

Overview of Study Design, Consisting of Four Age Cohorts That Were Assessed Annually for 3 Years

				\mathbf{Ag}	Age (Years)	rs)			
	11	12	13	14 15 16 17	15	16		18	19
Cohort 11 X ^a	X^{a}	\mathbf{X}^{p}	Xc						
Cohort 13			\mathbf{x}^{a}	\mathbf{x}^{p}	\mathbf{x}^{c}				
Cohort 15					\mathbf{X}^{a}	\mathbf{X}^{p}	\mathbf{x}^{c}		
Cohort 17							\mathbf{X}^{a}	X ^a X ^b X ^c	Xc
Cohort 11, <i>N</i> = 24–26; Cohort 13, <i>N</i> = 26–27; Cohort 15, <i>N</i> = 37–39; Cohort 17, <i>N</i> = 20–22.	r= 24-	26; Co	hort 1.	3, <i>N</i> =	26–27	; Coh	ort 15,	N=3	7–39; (
^a Assessment year 1.	year 1								
$b_{\rm Assessment}$ year 2.	year 2								
$c_{\rm Assessment vear 3}$	vear 3								

Table 2.

Descriptive Statistics of Non-Transformed Salivary Cytokines in Healthy Adolescent Girls at Each Assessment Year (pg/ml)

1 1.14 1.89 0.00 6.96 0.00 0.00 p70 0.35 1.10 0.00 10.09 0.00 0.00 p70 0.74 1.03 0.00 7.62 0.61 0.00 p70 0.74 1.03 0.00 7.62 0.61 0.00 176 1.40 3.27 0.00 5.77 0.68 0.36 176 1.40 3.27 0.00 5.71 0.76 0.36 176 1.40 3.27 0.00 5.77 0.78 0.76 176 1.40 3.27 0.00 5.77 0.78 0.76 176 0.90 17.36 1.43 0.76 0.76 0.76 577 0.14 1.76 0.00 5.77 0.78 0.00 570 0.19 7.73 0.78 0.76 0.76 571 1.34 0.73 1.368 0.36 0.76 57		Mean	SD	Minimum	Maximum	Median	25th Percentile	75th Percentile
114 1.89 0.00 6.96 0.00 0.00 70 0.35 1.10 0.00 10.09 0.00 0.00 70 0.74 1.03 0.00 7.62 0.61 0.00 70 75.84 88.44 1.54 530.61 51.92 23.11 1.76 1.40 0.00 6.92 1.43 0.76 1.76 1.40 0.00 6.92 1.43 0.76 1.76 1.40 0.00 6.92 1.43 0.76 61.26 63.13 0.43 316.86 43.16 17.76 0.90 1.07 0.00 17.36 1.96 0.36 191 2.35 3.45 0.00 1.76 0.36 191 0.74 0.00 17.36 1.96 0.36 191 0.75 0.00 1.345 0.76 0.36 191 0.74 0.00 1.345 0.76 0.36	1							
0.35 1.10 0.00 10.09 0.00 0.00 p70 0.74 1.03 0.00 7.62 0.61 0.00 p70 7.584 88.44 1.54 530.61 51.92 23.11 1.76 1.40 0.00 6.92 1.43 0.76 1.76 1.40 0.00 577 0.68 0.33 61.26 63.13 0.43 316.86 43.16 1776 57 0.90 1.736 1.96 0.90 61.26 63.13 0.43 316.86 43.16 1776 57 0.90 17.36 1.96 0.90 0.90 61.2 0.43 316.86 43.16 1776 67.1 2.345 0.00 3.45 0.00 0.90 70 0.44 0.74 0.78 0.76 0.90 71 1.57 1.96 0.53 0.55 0.90 715 1.54 0.74<	۲V	1.14	1.89	0.00	6.96	0.00	0.00	3.14
776 0.74 1.03 0.00 7.62 0.61 0.00 75.84 88.44 1.54 530.61 51.92 23.11 1.76 1.40 0.00 6.92 1.43 0.76 1.76 1.40 0.00 577 0.68 0.36 61.26 63.13 0.43 316.86 43.16 17.76 757 0.30 17.36 1.96 0.95 0.00 757 0.36 0.316 1.97 0.78 0.00 757 0.35 3.45 0.00 17.36 1.96 0.95 70 0.49 0.74 0.00 17.36 1.96 0.90 70 0.49 0.74 0.00 17.36 0.90 0.90 71 1.97 1.96 0.93 35.82 19.05 71 0.49 0.74 0.99 0.55 0.90 757 1.97 9.133 35.82 19.05 0.90<	.10	0.35	1.10	0.00	10.09	0.00	0.00	0.00
75.84 88.44 1.54 530.61 51.92 23.11 1.76 1.40 0.00 6.92 1.43 0.76 1.40 3.27 0.00 5.71 0.68 0.36 61.26 63.13 0.43 316.86 43.16 17.76 61.26 63.13 0.00 5.77 0.78 0.36 61.26 63.13 0.00 5.77 0.78 0.36 61.28 0.90 10.76 1.96 0.00 0.36 1.94 2.78 0.00 17.36 1.96 0.00 $p70$ 0.49 0.74 0.00 0.00 0.00 $p70$ 0.49 0.76 $0.31.33$ $3.5.82$ 19.05 $p70$ 0.46 0.00 0.76 0.76 0.76 $p70$ 0.46 0.74 0.76 0.76 0.76 $p70$ 0.66 <t< td=""><td>.12p70</td><td>0.74</td><td>1.03</td><td>0.00</td><td>7.62</td><td>0.61</td><td>0.00</td><td>0.97</td></t<>	.12p70	0.74	1.03	0.00	7.62	0.61	0.00	0.97
	.1β	75.84	88.44	1.54	530.61	51.92	23.11	85.59
	2	1.76	1.40	0.00	6.92	1.43	0.76	2.21
61.26 63.13 0.43 316.86 43.16 17.76 C 0.90 1.07 0.00 5.77 0.78 0.00 CSF 3.25 3.45 0.00 1.736 1.96 0.95 CSF 3.25 3.45 0.00 17.36 1.96 0.05 $p70$ 0.49 0.75 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.582 19.05 1.57 1.967 3.36 0.60 0.00 0.00 0.89 10725 1.816 $3.35.82$ 19.05 1.57 1.976 0.74 0.99 0.55 0.863 0.72 0.146 0.31 0.74 <	9	1.40	3.27	0.00	27.12	0.68	0.36	1.18
t 0.90 1.07 0.00 5.77 0.78 0.00 SF 3.25 3.45 0.00 17.36 1.96 0.95 F 1.94 2.78 0.00 17.36 1.96 0.95 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.99 0.74 0.00 3.45 0.00 0.00 1.57 1.96 0.00 3.45 0.00 0.00 1.57 1.96 0.00 1.441 0.99 0.55 0.89 1.72 0.00 14.41 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.00 54.95 10725 1.87 816.83 25.50 10.76 1.71 2.24 0.00 1.441 0.99 0.55 0.46 0.00 26.47 1.34 0.76 0.76 0.00 7.44 0.00 0.00 $p70$ 0.63 0.76 0.00 5.25 0.59 $p70$ 0.618 63.54 4.37 310.25 46.07 1.70 2.51 0.00 2.526 0.59 0.00 $p70$ 0.618 63.54 4.37 310.25 0.59 1.04 2.51 0.00 2.526 0.59 0.00 1.04 2.51 0.00 2.429 0.54 0.7	8	61.26	63.13	0.43	316.86	43.16	17.76	79.29
SF 3.25 3.45 0.00 17.36 1.96 0.95 $p70$ 1.94 2.78 0.00 12.200 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 1.441 0.99 0.55 1.57 1.96 0.00 14.41 0.99 0.56 0.89 1.72 0.00 14.41 0.99 0.55 0.89 1.72 0.00 14.41 0.99 0.56 0.89 1.72 0.00 14.41 0.99 0.56 0.89 1.72 0.90 0.56 0.56 0.76 0.89 0.75 0.59 0.56 0	Fa	06.0	1.07	0.00	5.77	0.78	0.00	1.35
	A-CSF	3.25	3.45	0.00	17.36	1.96	0.95	4.01
1.94 2.78 0.00 12.200 0.00 0.00 $p70$ 0.18 0.55 0.00 3.45 0.00 0.00 $p70$ 0.49 0.74 0.00 5.48 0.51 0.00 1.57 1.96 0.00 5.48 0.51 0.00 1.57 1.96 0.00 14.41 0.99 0.55 1.57 1.96 0.00 14.41 0.99 0.55 0.89 1.72 0.00 14.41 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.31 54.95 107.25 1.87 816.83 25.50 10.76 1.72 0.92 0.00 4.59 0.58 0.00 1.71 2.24 3.36 0.00 26.47 1.34 0.76 1.71 2.24 3.36 0.00 7.44 0.00 0.00 $p70$ 0.65 0.92 0.00 5.25 0.59 0.00 $p70$ 0.66 0.00 5.26 0.76 0.00 0.00 $p70$ 0.66 0.00 5.25 0.59 0.76 1.72 0.00 5.25 0.50 0.00 1.74 0.86 0.00 0.00 0.00 1.71 2.24 0.00 0.00 0.00 1.71 2.24 0.00 0.00 0.00 1.74 0.65 0.76 0.76 1.74 0.00 0.25 <td>5</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	5							
p_{70} 0.18 0.55 0.00 3.45 0.00 0.00 p_{70} 0.49 0.74 0.00 5.48 0.51 0.00 1.57 1.96 0.00 5.48 0.51 0.00 1.57 1.96 0.00 1.441 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.31 0.89 1.72 0.00 13.03 0.46 0.31 0.89 1.72 0.00 13.03 0.46 0.31 0.89 1.72 0.00 13.03 0.46 0.31 0.89 1.72 0.90 13.03 0.46 0.76 0.65 0.92 0.00 26.47 1.34 0.76 0.44 0.80 0.76 0.76 0.76 0.66 0.66 0.00 0.00 0.00 0.74 0.86 0.76 <	λ_{γ}	1.94	2.78	0.00	12.200	0.00	0.00	3.69
p70 0.49 0.74 0.00 5.48 0.51 0.00 1.57 1.96 0.00 1.41 0.99 0.55 1.57 1.96 0.00 14.41 0.99 0.55 1.57 1.96 0.00 14.41 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.31 64.95 0.00 13.03 0.46 0.31 64.95 0.00 4.59 0.58 0.00 54.95 0.76 0.00 4.59 0.76 0.76 0.44 3.36 0.00 7.44 0.00 0.00 $p70$ 0.64 0.00 5.25 0.76 0.00 $p70$ 0.64 0.00 5.26 0.00 0.00 $p70$ 0.64 0.00 5.25 0.59 0.00 $p70$ 0.66 0.00 5.25	-10	0.18	0.55	0.00	3.45	0.00	0.00	0.00
69.88 105.91 1.67 913.53 35.82 19.05 1.57 1.96 0.00 14.41 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.31 54.95 107.25 1.87 816.83 25.50 10.76 6.49 0.56 0.92 0.00 4.59 0.58 0.00 54.95 107.25 1.87 816.83 25.50 10.76 54.95 0.726 0.00 4.59 0.58 0.00 57.4 3.36 0.00 26.47 1.34 0.74 1.71 2.24 0.30 7.44 0.00 0.00 $p70$ 0.65 0.76 0.00 5.25 0.59 0.00 $p70$ 0.66 0.86 0.00 5.25 0.59 0.00 $p70$ 0.66 0.66 0.26 0.20 0.00	-12p70	0.49	0.74	0.00	5.48	0.51	0.00	0.72
1.57 1.96 0.00 14.41 0.99 0.55 0.89 1.72 0.00 13.03 0.46 0.31 54.95 107.25 1.87 816.83 25.50 10.76 1.71 0.65 0.92 0.00 4.59 0.58 0.00 $2SF$ 2.44 3.36 0.00 4.59 0.58 0.00 1.71 2.24 0.00 7.44 0.00 0.00 $p70$ 0.63 0.00 5.25 0.59 0.00 $p70$ 0.63 0.76 0.00 0.00 $p70$ 0.63 0.76 0.00 0.00 $p70$ 2.51 0.00 5.25 0.59 0.00 $p70$ 2.51 0.00 24.29 0.72 1.70 2.51 0.00 24.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	-1ß	69.88	105.91	1.67	913.53	35.82	19.05	95.56
	5	1.57	1.96	0.00	14.41	0.99	0.55	1.95
54.95 107.25 1.87 816.83 25.50 10.76 0.65 0.92 0.00 4.59 0.58 0.00 CSF 2.44 3.36 0.00 4.59 0.58 0.00 CSF 2.44 3.36 0.00 26.47 1.34 0.74 1.71 2.24 0.00 7.44 0.00 0.00 $p70$ 0.63 0.76 0.00 5.25 0.59 0.00 $p70$ 0.65 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 2.560 1.29 0.72 1.70 2.51 0.00 24.29 0.54 0.30 1.04 2.51 0.83 186.77 35.23 16.93	ę	0.89	1.72	0.00	13.03	0.46	0.31	0.66
t 0.65 0.92 0.00 4.59 0.58 0.00 SSF 2.44 3.36 0.00 26.47 1.34 0.74 SSF 2.44 3.36 0.00 26.47 1.34 0.74 1.71 2.24 0.00 7.44 0.00 0.00 p70 0.63 0.76 0.00 5.25 0.59 0.00 p70 0.65 66.18 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	œ	54.95	107.25	1.87	816.83	25.50	10.76	56.92
SSF 2.44 3.36 0.00 26.47 1.34 0.74 1.71 2.24 0.00 7.44 0.00 0.00 p70 0.44 0.88 0.00 6.49 0.00 0.00 p70 0.63 0.76 0.00 5.25 0.59 0.00 p70 0.65 4.37 310.25 46.07 21.86 1.70 2.51 0.00 24.29 0.72 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	IFα	0.65	0.92	0.00	4.59	0.58	0.00	0.93
1.71 2.24 0.00 7.44 0.00 0.00 p70 0.44 0.88 0.00 6.49 0.00 0.00 p70 0.63 0.76 0.00 5.25 0.59 0.00 p71 2.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	A-CSF	2.44	3.36	0.00	26.47	1.34	0.74	3.09
1.71 2.24 0.00 7.44 0.00 0.00 0.44 0.88 0.00 6.49 0.00 0.00 570 0.63 0.76 0.00 5.25 0.59 0.00 66.18 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93								
0.44 0.88 0.00 6.49 0.00 0.00 0.00 0.63 0.76 0.00 5.25 0.59 0.00 66.18 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	γγ	1.71	2.24	0.00	7.44	0.00	0.00	3.56
0.63 0.76 0.00 5.25 0.59 0.00 66.18 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	-10	0.44	0.88	0.00	6.49	0.00	0.00	1.03
66.18 63.54 4.37 310.25 46.07 21.86 1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	.12p70	0.63	0.76	0.00	5.25	0.59	0.00	0.87
1.70 2.51 0.00 25.60 1.29 0.72 1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	.1β	66.18	63.54	4.37	310.25	46.07	21.86	82.23
1.04 2.51 0.00 24.29 0.54 0.30 50.16 44.24 0.83 186.77 35.23 16.93	-2	1.70	2.51	0.00	25.60	1.29	0.72	2.03
50.16 44.24 0.83 186.77 35.23 16.93	-9	1.04	2.51	0.00	24.29	0.54	0.30	0.98
	IL-8	50.16	44.24	0.83	186.77	35.23	16.93	69.49

Author Manuscript

	Mean	SD	Minimum	Maximum	Median	Mean SD Minimum Maximum Median 25th Percentile 75th Percentile	75th Percentile
TNFa	0.87	0.87 0.90	00.0	5.99	0.78	0.00	1.28
GM-CSF 2.55 2.37	2.55	2.37	0.00	11.37	1.79	1.03	2.87
Descriptive sta	tistics wer	e calculat	ed across coho	orts. $N = 113 \text{fc}$	or year 1, N	Descriptive statistics were calculated across cohorts. $N = 113$ for year 1, $N = 114$ for year 2, $N = 107$ for year 3.	T = 107 for year 3.

Author Manuscript

Descriptive Statistics of Non-Transformed Serum Cytokines in Healthy Adolescent Girls at Each Assessment Year (pg/ml)

	Mean	SD	Minimum	Maximum	Median	25th Percentile	75th Percentile
Year 1							
$IFN\gamma$	9.60	46.34	0.00	411.78	0.00	0.00	2.90
IL-10	32.93	120.17	0.00	1127.08	7.17	3.91	11.97
IL-12p70	30.04	115.13	0.00	1001.60	1.35	0.00	6.83
IL-1β	12.28	43.61	0.00	417.37	1.88	0.00	6.05
IL-2	19.34	62.37	0.00	613.79	5.44	1.14	11.17
IL-6	10.35	27.12	0.00	173.81	1.41	0.71	4.35
IL-8	8.09	7.49	0.00	62.42	6.92	4.94	9.02
TNFa	9.75	7.56	0.70	51.70	8.60	6.06	10.98
GM-CSF	98.91	285.31	0.00	2353.39	16.40	0.00	65.35
Year 2							
IFN γ	3.37	17.36	0.00	172.78	0.00	0.00	0.67
IL-10	17.72	53.17	0.37	506.25	6.28	4.26	11.42
IL-12p70	12.70	49.77	0.00	467.98	0.59	0.00	5.42
IL-1β	9.83	53.07	0.00	558.43	1.17	0.00	4.20
IL-2	13.99	67.94	0.00	720.55	3.60	0.63	90.00
IL-6	7.31	26.19	0.00	244.17	1.76	0.96	4.32
IL-8	7.36	6.34	1.49	64.69	6.36	4.99	7.79
TNFa	8.32	4.27	2.02	27.73	7.52	5.29	10.26
GM-CSF	79.03	336.62	0.00	3493.67	0.00	0.00	54.45
Year 3							
IFN γ	187.04	349.14	0.00	1688.08	53.02	5.44	197.28
IL-10	52.94	307.86	0.00	2872.73	2.99	1.45	8.20
IL-12p70	266.86	887.06	0.00	5276.33	7.37	1.06	44.73
IL-1β	10.96	60.92	0.00	584.28	0.33	0.00	2.62
IL-2	30.33	111.41	0.00	694.30	2.16	0.32	9.23
IL-6	38.62	96.83	0.00	560.63	7.48	1.54	20.57
IL-8	54.39	74.84	3.75	319.26	24.07	9.21	57.02

Table 4.

Intercorrelations Within Salivary Cytokines and Within Serum Cytokines at the First Assessment Year, Controlling for Age

	IL-12p70	IL-1β IL-2	IL-2	IL-6	IL-8	TNFa	GM-CSF
IL-12p70		.58*	.61	* 68.	.33 *	.22	.50*
IL-1β	.54*		.82*	.48*	.37 *	.35 *	.76*
IL-2	* <i>LT.</i>	.75*		.49*	.36*	.31 *	.75*
IL-6	.57*	.51*	.63 *		.31 *	.20	.39*
IL-8	.71*	.72*	.93*	.61 *		.53*	.39*
TNFa	.66 [*]	.57*	.65 *	.54*	.66*		.24
GM-CSF	.75*	.71*	.91	.68	* 68.	.65 *	

Partial correlations for the salivary cytokines can be found below the diagonal; the serum correlations are presented above the diagonal.

p < .002 (Bonferroni-corrected alpha). N = 113.

Table 5.

Correlations of Cytokine Concentrations Over Time in Serum and Saliva, Controlling for Age

		Serum			Saliva	
	Years 1 and 2	Years 2 and 3	Years 1 and 3	Years 1 and 2	Years 2 and 3	Years 1 and 3
IL-12p70	.72*	.49 *	.41 *	.24	60.	.22
IL-1β	.75 *	.29*	.45 *	.37*	$.36^*$.46*
IL-2	.73*	.54 *	.57*	.31*	.26	.31 *
IL-6	.70*	.40*	$.50^*$.21	$.30^*$.19
IL-8	.53*	.17	.16	.38*	.28*	.45 *
TNFa	.39*	.10	.29*	.33*	.18	.35 *
GM-CSF	.53*	.29*	.39*	.25	.28*	.43

ġ 2 Years 1 and 2, N = 113; years 2 and 3, N

p < .007 (Bonferroni-corrected alpha).

Table 6.

Correlations of Serum and Salivary Cytokines With Adiponectin for the First Assessment Year, Controlling for Age

	Serum	Saliva
IL-12p70	08	.51*
IL-1β	01	.77*
IL-2	.00	.69*
IL-6	01	.62*
IL-8	07	.71*
TNFa	.00	.46*
GM-CSF	05	.68*

N=113.

 $p^* < .007$ (Bonferroni-corrected alpha).

Table 7.

Correlations Between Salivary and Serum Cytokines at the First Assessment Year, Controlling for Age

	Correlation With Serum Levels
IL-12p70	11
IL-1β	.11
IL-2	01
IL-6	.07
IL-8	05
TNFa	08
GM-CSF	07

N=113.

Table 8.

Regression Analyses for Each Cytokine Predicting Salivary Levels From Serum Levels, Controlling for Age, Adiponectin, and Smoking (First Assessment Year)

	В	SE	ß	Т	d	R^2	F	R^2
IL-12p70								
Step 1						0.31	19.30^{**}	
Age	-0.01	0.01	12	-1.27	.21			
Adiponectin	0.13	0.02	.49	7.03	<.01			
Smoking	-0.07	0.05	12	-1.33	.19			
Step 2						0.32	14.59 ^{**}	0.004
Serum levels	-0.01	0.01	06	-0.87	.39			
IL-1β								
Step 1						0.60	61.12 **	
Age	-0.03	0.03	07	-1.01	.32			
Adiponectin	0.92	0.07	.76	12.80	<.01			
Smoking	-0.05	0.16	02	-0.28	.78			
Step 2						0.61	48.48 **	0.014
Serum levels	0.11	0.07	.12	1.61	.11			
IL-2								
Step 1						0.52	51.78**	
Age	-0.03	0.01	16	-1.96	.05			
Adiponectin	0.27	0.02	99.	11.58	<.01			
Smoking	-0.06	0.06	07	-0.89	.38			
Step 2						0.52	39.58 ^{**}	0.000
Serum levels	0.00	0.02	01	-0.09	.93			
1IL-6								
Step 1						0.44	19.56^{**}	
Age	-0.02	0.01	12	-1.04	.17			
Adiponectin	.23	0.03	09.	7.08	<.01			
Smoking	-0.09	0.05	12	-1.87	.06			

	В	SE	<u>n</u>	7	4	- N	4	4
Step 2						0.45	14.42 **	0.006
Serum levels	0.02	0.02	.08	0.96	.34			
IL-8								
Step 1						0.55	74.03 **	
Age	-0.09	0.04	19	-2.35	.02			
Adiponectin	0.79	0.05	.68	14.73	<.01			
Smoking	-0.15	0.19	07	79	.43			
Step 2						0.55	60.38 ^{**}	0.000
Serum levels	-0.01	0.12	01	-0.12	.91			
TNFa								
Step 1						0.29	25.27 **	
Age	-0.04	0.01	26	-2.63	.01			
Adiponectin	0.16	0.03	44.	5.80	<.01			
Smoking	-0.01	0.08	02	-0.15	.88			
Step 2						0.29	18.88^{**}	0.006
Serum levels	-0.06	0.08	08	-0.73	.47			
GM-CSF								
Step 1						0.56	50.83	
Age	-0.06	0.02	24	-3.43	<.01			
Adiponectin	0.40	0.04	.61	11.03	<.01			
Smoking	-0.19	0.08	15	-2.46	.02			
Step 2						0.56	40.07	0.002
Serum levels	-0.01	0.02	04	-0.66	.51			